These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 8097711

  • 1. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.
    Ahluwalia G, Cooney DA, Hartman NR, Mitsuya H, Yarchoan R, Fridland A, Broder S, Johns DG.
    Drug Metab Dispos; 1993; 21(2):369-76. PubMed ID: 8097711
    [Abstract] [Full Text] [Related]

  • 2. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.
    Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S, Johns DG.
    Mol Pharmacol; 1991 Jul; 40(1):118-24. PubMed ID: 1677450
    [Abstract] [Full Text] [Related]

  • 3. Enhanced stimulation by ribavirin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of purine 2'-beta-fluoro-2',3'-dideoxynucleosides.
    Johns DG, Ahluwalia GS, Cooney DA, Mitsuya H, Driscoll JS.
    Mol Pharmacol; 1993 Sep; 44(3):519-23. PubMed ID: 8371712
    [Abstract] [Full Text] [Related]

  • 4. Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine.
    Ahluwalia GS, Cooney DA, Shirasaka T, Mitsuya H, Driscoll JS, Johns DG.
    Mol Pharmacol; 1994 Nov; 46(5):1002-8. PubMed ID: 7969062
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of the anti-HIV-1 activity of ddAdo by coformycin, EHNA and deaza-EHNA derivatives.
    Marongiu ME, Pani A, Tinti E, Grifantini M, Franchetti P, Cristalli G, La Colla P.
    New Microbiol; 1995 Oct; 18(4):359-70. PubMed ID: 8590388
    [Abstract] [Full Text] [Related]

  • 6. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells.
    Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG, Fridland A.
    J Biol Chem; 1988 Oct 25; 263(30):15354-7. PubMed ID: 3262616
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus.
    Balzarini J, Lee CK, Herdewijn P, De Clercq E.
    J Biol Chem; 1991 Nov 15; 266(32):21509-14. PubMed ID: 1939181
    [Abstract] [Full Text] [Related]

  • 8. Interpretation of the roles of adenylosuccinate lyase and of AMP deaminase in the anti-HIV activity of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.
    Nair V, Sells TB.
    Biochim Biophys Acta; 1992 Feb 26; 1119(2):201-4. PubMed ID: 1540653
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP, Nandy P, Avramis VI.
    In Vivo; 2000 Feb 26; 14(3):377-88. PubMed ID: 10904870
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cellular phosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key intermediate in the activation of the antiviral agent DDI, in human peripheral blood mononuclear cells.
    Robbins BL, Greenhaw J, Fridland A.
    Nucleosides Nucleotides Nucleic Acids; 2000 Feb 26; 19(1-2):405-13. PubMed ID: 10772723
    [Abstract] [Full Text] [Related]

  • 14. Enzymatic phosphorylation and pyrophosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2',3'-dideoxyinosine.
    Navé JF, Eschbach A, Wolff-Kugel D, Halazy S, Balzarini J.
    Biochem Pharmacol; 1994 Sep 15; 48(6):1105-12. PubMed ID: 7945403
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of 2',3'-dideoxyadenosine in dogs.
    Wientjes MG, Placke ME, Chang MJ, Page JG, Kluwe WM, Tomaszewski JE.
    Invest New Drugs; 1991 May 15; 9(2):159-68. PubMed ID: 1908444
    [Abstract] [Full Text] [Related]

  • 16. Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells.
    Gao WY, Mitsuya H, Driscoll JS, Johns DG.
    Biochem Pharmacol; 1995 Jul 17; 50(2):274-6. PubMed ID: 7632173
    [Abstract] [Full Text] [Related]

  • 17. Decay rates of anti-HIV dideoxynucleotides in tissue culture systems: a simple correction for the effect of cell replication.
    Ahluwalia GS, Dedrick RL, Driscoll JS, Morrison PF, Gao WY, Johns DG.
    Drug Metab Dispos; 1997 Jul 17; 25(7):893-6. PubMed ID: 9224785
    [Abstract] [Full Text] [Related]

  • 18. Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.
    Le Saint C, Terreux R, Duval D, Durant J, Ettesse H, Dellamonica P, Guedj R, Vincent JP, Cupo A.
    Antimicrob Agents Chemother; 2004 Feb 17; 48(2):589-95. PubMed ID: 14742213
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.